Innovative Pharmaceutical Biotech (HKG:0399) expects to swing to a loss for the year ended March 31, according to a bourse filing Monday.
Shares declined 5% in morning trade Tuesday.
The pharma company is estimating a loss of between HK$550 million and HK$600 million, which compares to a profit of HK$98.7 million for fiscal 2024.
The company attributed the loss to a "significant impairment loss" on an intangible asset.
Innovative Pharmaceutical expects to report its annual results at the end of June.
Meanwhile, the company said its oral insulin product is now expected to enter the market in the third quarter of 2028.
The company had originally planned to commercialize the product in the first quarter of 2026, but said was delayed due to difficulty in onboarding subjects into its phase 3 clinical trial.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。